Pharmaceutical expenditures account for approximately 15.9 % of total health expenditures in Canada. Unlike hospital and physician services, in which costs are universally covered, most pharmacological therapy does not fall under the umbrella of ‘medically necessary’ services set out by the Canada Health Act, and therefore is funded through a mix of public and private plans. Little is known about the actual financial burden experienced by Canadians from out-of-pocket drug expenditures (OOPDE). This paper examines the burden of OOPDE in Canada. 1.1 % of Canadian households exceed our catastrophic threshold (9 %) of the drug budget share. Additionally, 2.6 and 8.2 % of households exceed lower thresholds of 6 and 3 % respectively. We find an inverse relationship between household income and the burden of OPPDE. Low-income households have the highest likelihood of being in the ‘catastrophic’ drug expenditure category. This finding suggests that a vulnerable population of ‘working poor’ are likely to be experiencing disproportionate financial burden because they are not eligible for public assistance programs. Seniors experience the highest burden of OPPDE when compared to other age groups. We also find that there is significant interprovincial variation in the burden of OOPDE, which partly reflects different provincial government drug coverage policies.
This is a preview of subscription content,to check access.
Access this article
Similar content being viewed by others
Alan, S., Crossley, T. F., Grootendorst, P., & Veall, M. R. (2002). The effects of drug subsidies on out-of-pocket prescription drug expenditures by seniors: Regional evidence from Canada. Journal of Health Economics, 21(5), 805–826.
Alan, S., Crossley, T. F., Grootendorst, P., & Veall, M. R. (2005). Distributional effects of ‘general population’prescription drug programs in Canada. Canadian Journal of Economics, 38(1), 128–148.
Canadian Institute for Health Information CIHI. (2013, April 11). National Health Expenditure Trends, 1985 to 2012. Canadian Institute for Health Information.
Coombes, M., Morgan, S., Barer, M., & Pagliccia, N. (2004). Who’s the fairest of them all? Which provincial pharmacare model would best protect Canadians against catastrophic drug costs. Longwood Review, 3, 13–26.
Daw, J. R., & Morgan, S. G. (2012). Stitching the gaps in the Canadian public drug coverage patchwork? A review of provincial pharmacare policy changes from 2000 to 2010. Health Policy, 104(1), 19–26.
Health Canada. (2006). National Pharmaceutical Strategy Progress Report.
Kapur, V., & Basu, K. (2005). Drug coverage in Canada: Who is at risk? Health Policy, 71(2), 181–193.
Law, M. R., Cheng, L., Dhalla, I. A., Heard, D., & Morgan, S. G. (2012). The effect of cost on adherence to prescription medications in Canada. Canadian Medical Association Journal, 184, 297–302.
Luczak, J., & Garcia-Gomez, P. (2012). Financial burden of drug expenditures in Poland. Health Policy, 105(2–3), 256–64.
McLeod, L., Bereze, B. G., Shim, M., & Grootendorst, P. (2011). Financial burden of household out-of-pocket expenditures for prescription drugs: Cross-sectional analysis based on national survey data. Open Medicine, 5, 1.
Rogowski, J., Lillard, L. A., & Kington, R. (1997). The financial burden of prescription drug use among elderly persons. The Gerontologist, 37(4), 475–482.
Romanow, R. (2002). Building on values: The future of health care in Canada. Saskatoon: Commision on the Future of Health Care in Canada.
Statistics Canada. (2010). Survey of household spending, April 4, 2012.
This analysis was funded by the School of Public Health at the University of Saskatchewan.
See Table 5.
About this article
Cite this article
Caldbick, S., Wu, X., Lynch, T. et al. The financial burden of out of pocket prescription drug expenses in Canada. Int J Health Econ Manag. 15, 329–338 (2015). https://doi.org/10.1007/s10754-015-9171-3